Target intelligence / Profile preview

SARS-CoV-2 envelope protein (E protein)

Target
E protein
Molecular classification
Viroporin (viral ion channel), Integral membrane protein, Structural protein
01

Overview

The SARS-CoV-2 envelope protein is one of four major structural proteins in the virus, consisting of 75 amino acids forming a single α-helical transmembrane segment and a short cytoplasmic tail featuring a PDZ-binding motif linked to virulence[3][4][9]. It assembles into a pentameric cation channel (viroporin) in the ER-Golgi intermediate compartment (ERGIC) membrane, facilitating ion (notably Na+ and Ca2+) conduction critical for viral assembly, budding, release, and pathogenicity[1][9]. The protein also mediates interactions with viral and host proteins, including cell junction and immune receptors, promoting viral egress and contributing to virulence[7][9]. Inhibitors targeting the envelope protein’s channel activity (e.g., hexamethylene amiloride) are under active investigation as antiviral agents[1][2][9]. The E protein is highly conserved across SARS-CoV-2 variants, and its C-terminal PBM is recognized as a determinant of disease severity[3][4][7][9].

Other names
Envelope protein (E protein)SARS-CoV-2 ECoronavirus E proteinViroporin E
02

Mechanism of action

Ion channel inhibition (viroporin inhibition); Interference with protein-protein interactions relevant for viral assembly and virulence (e.g., blocking E-PALS1 interactions)

03

Biological functions

Virion assemblyBuddingReleaseVirus pathogenicityIon channel activity (cation conduction)Membrane curvature sensingInteraction with host proteins (e.g., PALS1, Toll-like receptor 2)
04

Disease associations

Infection (COVID-19)Virus replicationViral pathogenesis
05

Safety considerations

Therapeutic targeting of viroporins like E could affect ion balances in host cellsSmall molecule inhibitors must avoid host toxicity due to similar ion channel functions
06

Interacting drugs

Hexamethylene amiloride (HMA)

3 more in the full profile.

07

Biomarkers

Mutations in the E protein gene may affect viral pathogenicity and are monitored for variantsBinding affinity to inhibitors correlates with antiviral potencyC-terminal PDZ-binding motif (PBM) linked to disease severity and virulence

Beyond the preview

Go deeper on SARS-CoV-2 envelope protein (E protein).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SARS-CoV-2 envelope protein (E protein).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call